Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TAS2R46 | P59540 | 2/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8104271 | 1.00 | CA1 (0.41) | CA1CA9SMN1; SMN2MEN1KMT2A | |
| SCHEMBL439067 | 1.00 | CA1 (0.41) | CA1CA9SMN1; SMN2MEN1KMT2A | |
| SCHEMBL682255 | 1.00 | CA1 (0.41) | CA1CA9SMN1; SMN2MEN1KMT2A | |
| SCHEMBL732959 | 1.00 | CA1 (0.41) | CA1CA9SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15034 | 1.00 | CA1 (0.41) | CA1CA9SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15195848 | 1.00 | CA1 (0.41) | CA1CA9SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2860232 | 1.00 | CA1 (0.41) | CA1CA9SMN1; SMN2MEN1KMT2A | |
| Methane SCHEMBL1276943 | 0.96 | CA1 (0.39) | CA1CA9SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2314693 | 0.96 | CA1 (0.39) | CA1CA9SMN1; SMN2MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL17351919 | 0.96 | CA1 (0.39) | CA1CA9SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1765 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119039216-B | Ion-pair pyridine bridged bisphenol oxyalkali metal complex and preparation method and application thereof | 华东理工大学 | 2026-05-15 | — | — | CN | claimed |
| CN-119039215-B | Dimethylenepyridine bridged amino bisphenol oxy alkali metal complex and preparation method and application thereof | 华东理工大学 | 2026-05-15 | — | — | CN | claimed |
| CN-116874754-B | Polymerization method of substituted glycolide | 华东理工大学 | 2026-05-15 | — | — | CN | claimed |
| CN-121779369-B | Method for preparing racemic lactide by catalyzing meso-lactide with auxiliary agent | 普立思生物科技有限公司 | 2026-05-15 | — | — | CN | claimed |
| CN-121159834-B | Colored polylactic acid oligomer, preparation method thereof and polylactic acid colorant | 青岛大学 | 2026-05-12 | — | — | CN | claimed |
| EP-3525722-B1 | DRUG ELUTING STENT FOR ENABLING RESTORATION OF FUNCTIONAL ENDOTHELIAL CELL LAYERS | SINO MEDICAL SCIENCES TECH INC (CN) | 2026-05-06 | — | — | EP | claimed |
| US-12590914-B2 | Method for analyzing content of D-lactic repeating units in polylactic acid | LG CHEM, LTD. (KR) | 2026-03-31 | — | — | US | claimed |
| US-12558089-B2 | Indirect attachment of a needle to a mesh suture | NORTHWESTERN UNIVERSITY (US) | 2026-02-24 | — | — | US | claimed |
| EP-4650381-A1 | A FLEXIBLE AND ECONOMICAL PROCESS AND PLANT FOR PRODUCING POLYLACTIC ACID | Sulzer Management AG (CH) | 2025-11-19 | — | — | EP | claimed |
| US-20250346715-A1 | PLANT AND EFFICIENT PROCESS FOR PRODUCING POLYLACTIC ACID | SULZER MANAGEMENT AG (CH) | 2025-11-13 | — | — | US | claimed |
| US-20070020312-A1 | Method of fabricating a bioactive agent-releasing implantable medical device | ADVANCED CARDIOSVASCULAR SYSTEMS, INC. | 2007-01-25 | — | — | US | claimed |
| US-20050165206-A1 | Method for producing melt-stable homo- and copolyesters of cyclic esters and/or diesters | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2005-07-28 | — | — | US | claimed |
| EP-1495063-A1 | METHOD FOR PRODUCING MELT-STABLE HOMO- AND COPOLYESTERS OF CYCLIC ESTERS AND/OR DIESTERS | FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2005-01-12 | — | — | EP | claimed |
| WO-2003087191-A1 | METHOD FOR PRODUCING MELT-STABLE HOMO- AND COPOLYESTERS OF CYCLIC ESTERS AND/OR DIESTERS | FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2003-10-23 | — | — | WO | claimed |
| EP-0372221-B1 | Continuous process for the preparation of resorbable polyesters, and their use | BOEHRINGER INGELHEIM PHARMA (DE) | 2000-01-19 | — | — | EP | claimed |
| US-5700901-A | INJECTION MOLDING A POLYLACTIDE | BOEHRINGER INGELHEIM KG (DE) | 1997-12-23 | — | — | US | claimed |
| EP-0401844-B1 | Resorbable moulded articles and method for their preparation | BOEHRINGER INGELHEIM KG (DE) | 1995-11-22 | — | — | EP | claimed |
| US-5378801-A | Sutures, polylactides | BOEHRINGER INGELHEIM GMBH D-55216 INGELHEIM AM RHEIN (DE) | 1995-01-03 | — | — | US | claimed |
| US-5053485-A | Biocompatibile copolymer, sutures and controlled release pharmceuticals; high speed biodegradation | C.C.A. BIOCHEM B.V. (NL) | 1991-10-01 | — | — | US | claimed |
| EP-0314245-A1 | Method for the preparation of a polymer lactide | Purac Biochem B.V. (NL) | 1989-05-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590914-B2 | Method for analyzing content of D-lactic repeating units in polylactic acid | PKLR, LRPPRC, PKM | CA1 1185/4885CA9 373/4885SMN1; SMN2 454/4885 |
| US-12558089-B2 | Indirect attachment of a needle to a mesh suture | MYH9, KRT18, DSP | CA1 3007/4885CA9 992/4885SMN1; SMN2 2608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.